Turbine secures £17.2m in Series A funding to advance its cancer cell simulation platform
The financing round was co-led by Mercia and MSD Global Health Innovation Fund.
Turbine operates a cell simulation platform designed to predict cancer treatment efficacy and improve drug discovery. The company is headquartered in London with additional offices in Budapest and Cambridge.
Turbine has secured £17.2m in a Series A financing round co-led by Mercia and MSD Global Health Innovation Fund. The raise included participation from Day One Capital and existing backers Accel, Delin Ventures, and XTX Ventures. The company intends to direct the proceeds towards advancing its artificial intelligence platform, growing its headcount, and forging commercial partnerships across the biopharmaceutical sector.
Originating as a spinout from the Technical University of Budapest, Turbine models the inner signalling network of cancer cells to assist pharmaceutical firms in identifying targets and overcoming therapy resistance. Its technology has already attracted collaborations with major industry players, including Bayer.
From the founder
"The idea sprung from our frustration that experiments frequently lead to expensive and time-consuming drug development failures,"
Szabolcs Nagy
Chief Executive Officer and Co-founder at Turbine
Investor perspective
"MSD GHI looks forward to enabling acceleration of Turbine’s growth and expansion,"
David Rubin
Managing Director, MSD Global Health Innovation Fund
Use of funds
- 01Continue product development
- 02Grow the team
Investors
Daniela Tsoneva
Mercia
David Rubin
MSD Global Health Innovation Fund
Day One Capital
Accel
Delin Ventures
XTX Ventures
